Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
225 SEK | -1.10% | -5.86% | +6.13% |
Apr. 25 | Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 25 | CellaVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 51% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 32.5 and 25.01 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.13% | 498M | C+ | ||
-14.56% | 18.57B | A | ||
+17.00% | 1.85B | - | - | |
-0.51% | 1.66B | - | ||
+26.33% | 1.23B | B+ | ||
-13.90% | 989M | - | ||
-21.76% | 896M | - | C- | |
-4.05% | 734M | - | ||
-19.85% | 667M | B+ | ||
-.--% | 303M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CEVI Stock
- Ratings CellaVision AB